When Does Stelara's Main Patent Expire?
Stelara (ustekinumab) has faced multiple patent challenges. The primary patent protecting Stelara, U.S. Patent No. 7,710,714, is set to expire on September 22, 2024 [1].
What Are the Key Patents Involved in Stelara Litigation?
Beyond the main patent, other patents related to Stelara's formulation and methods of use are also significant in ongoing litigation. For example, U.S. Patent No. 8,563,509, which covers a method of treating plaque psoriasis, is another patent that has been a subject of legal disputes [1].
How is Stelara's Patent Status Affecting Biosimilar Development?
The approaching expiry of Stelara's key patents is a critical factor for biosimilar manufacturers. Companies are actively developing biosimilar versions of ustekinumab, anticipating market entry upon patent expiry [2]. The outcome of patent litigation can significantly influence the timeline and feasibility of these biosimilar launches.
Which Companies Are Involved in Stelara Patent Litigation?
Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, holds the marketing exclusivity for Stelara. Several biosimilar companies, including Amgen, Samsung Bioepis, and Fresenius Kabi, have been involved in legal proceedings challenging Janssen's patents [1][2]. These challenges often involve Abbreviated New Drug Application (ANDA) litigation.
What Are the Potential Timelines for Stelara Biosimilar Launches?
While the main patent for Stelara expires in September 2024, the precise timing for biosimilar launches depends on the resolution of ongoing patent litigation. If patent challenges are resolved favorably for biosimilar manufacturers, launches could potentially occur in late 2024 or 2025. However, continued legal battles could delay market entry [1][2].
What Are the Risks Associated with Stelara Biosimilar Entry?
For biosimilar developers, risks include the potential for extended patent litigation, which can delay market entry and impact profitability. For patients and payers, the primary risk is the uncertainty surrounding the availability and pricing of biosimilars if patent disputes are prolonged or resolved in favor of the innovator drug [2].
How Does Stelara Compare to Other Biologics for Psoriasis?
Stelara is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It targets the IL-12 and IL-23 cytokines. Other biologics for psoriasis include TNF inhibitors (e.g., adalimumab, infliximab), IL-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., risankizumab) [3]. The development of Stelara biosimilars could offer a more cost-effective treatment option within this therapeutic landscape.
Where Can I Find More Information on Drug Patents?
Information on drug patents, including expiry dates and litigation, can be found on resources like DrugPatentWatch.com, which tracks intellectual property for pharmaceutical products [1].
Sources
1. DrugPatentWatch.com
2. Company press releases and litigation filings.
3. Published clinical trial data and drug information resources.